Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
about
Bariatric surgery for non-alcoholic steatohepatitis in obese patientsEffects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical TrialsGut Microbiota and Lifestyle Interventions in NAFLDDiet, Microbiota, Obesity, and NAFLD: A Dangerous QuartetInvolvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesityIntestinal microbiota in health and disease: role of bifidobacteria in gut homeostasisThe role of the gut microbiome in the pathogenesis and treatment of obesityTherapeutic options in pediatric non alcoholic fatty liver disease: current status and future directionsVSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.Gut microbiota and inflammation.Microbiota and gut-liver axis: their influences on obesity and obesity-related liver diseaseNonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.Innate immune dysfunction in acute and chronic liver disease.Probiotics and Nonalcoholic Fatty liver Disease.The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.Probiotics in hepatology.Role of the diet as a link between oxidative stress and liver diseasesNon-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic.Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease.Probiotics and gut health: a special focus on liver diseases.Pediatric non alcoholic fatty liver disease: more on novel treatment targets.Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration.The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention.The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.Treatment options for nonalcoholic fatty liver disease.Is there a role for probiotics in liver disease?
P2860
Q24240455-09803048-64EA-42E0-977B-7D0BB9141174Q26745869-C8315364-4342-4F27-957B-8B1C6C05C296Q26749783-718E424F-6909-4F79-9F15-CA2BB62E5FC7Q26752614-D0811915-A9A1-427F-BF31-3A53ECFFEF91Q26828547-DF30B451-BA54-4276-A7C3-F4BAA90E600DQ27001712-35A43201-7B62-4F06-BAC0-D67E083FD021Q27014922-C578C102-9DEB-4CA2-A261-657DE2C7A003Q27028844-43B0697C-497E-410C-87A3-7E4ABDA05C3FQ34428997-8324F487-A6E6-43F1-86AE-9A6ABD69DCDDQ34499017-46F1F7F3-D866-43A6-AB95-3AEC411F214CQ35670894-63CC46B1-F055-467B-B737-F3DF8124D67BQ36798196-AD5A7E15-91C9-4700-A6BC-5C5E23046799Q37149405-B83EF80E-B73D-4654-8E52-9150A2701A3EQ37666863-EDC85EAD-F076-48C8-A9D8-2C9777CBC140Q37708418-DAF01859-CD9A-42FD-B515-404B18CF95C0Q37729625-058FA1E9-2DA5-415C-951D-BA6C90560FD3Q37898517-1330C115-5021-4F5E-9BCC-98C8C97A9F61Q38320278-71581326-757C-44A3-AC73-22505C1CDAAEQ42406740-B49CCBC8-908F-43A0-9176-AD346AF96312Q42580307-9BA7D6C1-AA3F-4B29-B715-DFDC0487A2BAQ42930192-5CBF1342-F156-456C-AA5B-043F3AE31AD2Q43074168-2774AC85-F029-413D-B87E-5FEDA9C672FBQ50224112-9CBCD2E7-F24D-49DC-857A-621D81CF66DCQ53681665-7D174537-EC04-48C0-9D98-40DD7CA8A7EBQ55450597-75227AC5-28CA-4F36-8FC8-B1972D1FC6DFQ55460608-D1D8410A-06CC-46EA-8692-B92A65E27C27Q59101131-B6F39A15-02C1-40B3-863C-8BC1450AAD14
P2860
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
description
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2007/01/24)
@fr
articolo scientifico (pubblicato il 2007/01/24)
@it
artigo científico (publicado na 2007/01/24)
@pt
artikull shkencor
@sq
artículu científicu espublizáu en 2007
@ast
scientific article (published 2007-01-24)
@en
vedecký článok (publikovaný 2007/01/24)
@sk
vetenskaplig artikel (publicerad på 2007/01/24)
@sv
name
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@ast
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en-gb
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@nl
type
label
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@ast
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en-gb
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@nl
prefLabel
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@ast
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en-gb
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@nl
P2093
P2860
P3181
P1476
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis
@en
P2093
Ezio Mastropasqua
Flavio Lirussi
Rocco Orlando
Serena Orando
P2860
P3181
P356
10.1002/14651858.CD005165.PUB2
P577
2007-01-24T00:00:00Z